These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25576920)

  • 21. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
    Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
    PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma.
    Lai JP; Yu C; Moser CD; Aderca I; Han T; Garvey TD; Murphy LM; Garrity-Park MM; Shridhar V; Adjei AA; Roberts LR
    Gastroenterology; 2006 Jun; 130(7):2130-44. PubMed ID: 16762634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. mTOR kinase inhibitors promote antibody class switching via mTORC2 inhibition.
    Limon JJ; So L; Jellbauer S; Chiu H; Corado J; Sykes SM; Raffatellu M; Fruman DA
    Proc Natl Acad Sci U S A; 2014 Nov; 111(47):E5076-85. PubMed ID: 25385646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of apoptosis by trichostatin A, a histone deacetylase inhibitor, is associated with inhibition of cyclooxygenase-2 activity in human non-small cell lung cancer cells.
    Choi YH
    Int J Oncol; 2005 Aug; 27(2):473-9. PubMed ID: 16010430
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells.
    Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G
    J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.
    Dong LH; Cheng S; Zheng Z; Wang L; Shen Y; Shen ZX; Chen SJ; Zhao WL
    J Hematol Oncol; 2013 Jul; 6():53. PubMed ID: 23866964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting eIF4F translation complex sensitizes B-ALL cells to tyrosine kinase inhibition.
    Vo TT; Herzog LO; Buono R; Lee JS; Mallya S; Duong MR; Thao J; Gotesman M; Fruman DA
    Sci Rep; 2021 Nov; 11(1):21689. PubMed ID: 34737376
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling.
    Qian C; Lai CJ; Bao R; Wang DG; Wang J; Xu GX; Atoyan R; Qu H; Yin L; Samson M; Zifcak B; Ma AW; DellaRocca S; Borek M; Zhai HX; Cai X; Voi M
    Clin Cancer Res; 2012 Aug; 18(15):4104-13. PubMed ID: 22693356
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Use of a novel histone deacetylase inhibitor to induce apoptosis in cell lines of acute lymphoblastic leukemia.
    Romanski A; Bacic B; Bug G; Pfeifer H; Gul H; Remiszewski S; Hoelzer D; Atadja P; Ruthardt M; Ottmann OG
    Haematologica; 2004 Apr; 89(4):419-26. PubMed ID: 15075075
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia.
    Vilas-Zornoza A; Agirre X; Abizanda G; Moreno C; Segura V; De Martino Rodriguez A; José-Eneriz ES; Miranda E; Martín-Subero JI; Garate L; Blanco-Prieto MJ; García de Jalón JA; Rio P; Rifón J; Cigudosa JC; Martinez-Climent JA; Román-Gómez J; Calasanz MJ; Ribera JM; Prósper F
    Leukemia; 2012 Jul; 26(7):1517-26. PubMed ID: 22307227
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase I study of the mTOR inhibitor ridaforolimus and the HDAC inhibitor vorinostat in advanced renal cell carcinoma and other solid tumors.
    Zibelman M; Wong YN; Devarajan K; Malizzia L; Corrigan A; Olszanski AJ; Denlinger CS; Roethke SK; Tetzlaff CH; Plimack ER
    Invest New Drugs; 2015 Oct; 33(5):1040-7. PubMed ID: 26091915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pleiotropic antitumor effects of the pan-HDAC inhibitor ITF2357 against c-Myc-overexpressing human B-cell non-Hodgkin lymphomas.
    Zappasodi R; Cavanè A; Iorio MV; Tortoreto M; Guarnotta C; Ruggiero G; Piovan C; Magni M; Zaffaroni N; Tagliabue E; Croce CM; Zunino F; Gianni AM; Di Nicola M
    Int J Cancer; 2014 Nov; 135(9):2034-45. PubMed ID: 24648290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Induction of apoptosis by apicidin, a histone deacetylase inhibitor, via the activation of mitochondria-dependent caspase cascades in human Bcr-Abl-positive leukemia cells.
    Cheong JW; Chong SY; Kim JY; Eom JI; Jeung HK; Maeng HY; Lee ST; Min YH
    Clin Cancer Res; 2003 Oct; 9(13):5018-27. PubMed ID: 14581377
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cooperative Targets of Combined mTOR/HDAC Inhibition Promote MYC Degradation.
    Simmons JK; Michalowski AM; Gamache BJ; DuBois W; Patel J; Zhang K; Gary J; Zhang S; Gaikwad S; Connors D; Watson N; Leon E; Chen JQ; Kuehl WM; Lee MP; Zingone A; Landgren O; Ordentlich P; Huang J; Mock BA
    Mol Cancer Ther; 2017 Sep; 16(9):2008-2021. PubMed ID: 28522584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Curbing autophagy and histone deacetylases to kill cancer cells.
    Gammoh N; Marks PA; Jiang X
    Autophagy; 2012 Oct; 8(10):1521-2. PubMed ID: 22894919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combinatorial effects of histone deacetylase inhibitors (HDACi), vorinostat and entinostat, and adaphostin are characterized by distinct redox alterations.
    Rivera-Del Valle N; Cheng T; Irwin ME; Donnella H; Singh MM; Chandra J
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):483-495. PubMed ID: 29313067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors.
    Batista A; Barata JT; Raderschall E; Sallan SE; Carlesso N; Nadler LM; Cardoso AA
    Exp Hematol; 2011 Apr; 39(4):457-472.e3. PubMed ID: 21277936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. FoxO proteins' nuclear retention and BH3-only protein Bim induction evoke mitochondrial dysfunction-mediated apoptosis in berberine-treated HepG2 cells.
    Shukla S; Rizvi F; Raisuddin S; Kakkar P
    Free Radic Biol Med; 2014 Nov; 76():185-99. PubMed ID: 25128467
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histone deacetylase inhibitors induce autophagy through FOXO1-dependent pathways.
    Zhang J; Ng S; Wang J; Zhou J; Tan SH; Yang N; Lin Q; Xia D; Shen HM
    Autophagy; 2015 Apr; 11(4):629-42. PubMed ID: 25919885
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mammalian target of rapamycin inhibitor rapamycin enhances anti-leukemia effect of imatinib on Ph+ acute lymphoblastic leukemia cells.
    Yang X; He G; Gong Y; Zheng B; Shi F; Shi R; Yang X
    Eur J Haematol; 2014 Feb; 92(2):111-20. PubMed ID: 24112092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.